国家药品集中带量采购具有药品种类丰富、覆盖地域范围广泛的特点,对各个区域联盟开展药品集中带量采购提供了重要参考。本文选取“4+7”集采扩围、第二批至第五批国家药品集中带量采购以及2021年开展且公布中选数据的地区联盟药品集中带量采购作为研究对象,通过OLS回归模型分析国家药品集中带量采购对地区联盟集中采购是否存在价格变化的传导现象。结果显示,各批次国家药品集中带量采购对于地区联盟药品集中带量采购并不存在显著的价格传导效应,但该结果可能受获取的公开数据有限、各批次集采间重合品种少、采购量和中选规则存在差异等因素影响,并不能完全否认价格传导效应的存在。本文旨在深化对我国药品集中带量采购政策内涵及实施情况的理解,为药品集中带量采购改革的开展提供参考建议。

National centralized drug procurement involves diversified drug types and wide geographical area, which provides important reference for regional alliances to carry out centralized procurement. This paper takes the expansion of “4+7” centralized procurement, the second to fifth batch of national centralized drug procurements, and the centralized drug procurement of regional alliances with official data published before December 2021 as examples. OLS regression model is used to analyze whether national centralized drug procurements would have a price transmission effect on the centralized drug procurements of regional alliances. The result shows that there is no significant price transmission effect between national centralized drug procurements and the regional ones. However, this result may not completely deny the existence of price transmission effect due to limited available data, along with few overlapping drug types, different purchase amount and selection rules among the studied drug procurements. This paper aims to enrich the understanding of the connotation and implementation of the centralized drug procurement policy. Meanwhile, it provides some reference for the following centralized drug procurements.